A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

Summary

The objective of this study are to evaluate the safety and tolerability of ABT-199 (venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary objective is to explore clinical response to ABT-199 (venetoclax) in patients with advanced CTCL.

Timeline

Start

2020-01-15

Primary completion

2021-02-10

Completion

2021-06-22

Drugs

Indications